Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
New Case Study Details Productivity Gains, Process Improvements Realized with Quantros Accreditation and Compliance Excellence Solution
San Francisco, CA (PRWEB) July 21, 2009 -- Quantros, a leading provider of safety and quality software and professional services solut...
BD and FIND Achieve Milestone in Global Battle Against MDR-TB
Price reductions for liquid culture tests will accelerate access to improved TB diagnostics
SEATTLE, June 17 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company; NYSE: BDX ), a leading global medical technology company, and FIND (Foundation for Innovative New Diagnostics), a Swiss f...
LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting
Several of LASIK and refractive eye surgery experts listed at Trusted LASIK Surgeons were among those eye doctors honored at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Francisco, California. Dr. Parag Majmudar, Dr. Shachar Tauber, and Dr. William...
Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide
Hydrogen peroxide is one of the world's most versatile and widely used chemicals. A powerful oxidizing agent, H 2 O 2 is commonly used as a bleach, an antiseptic and a disinfectant.
Despite its importance, however, says Christopher J. Kiely, hydrogen peroxide has eluded the best efforts of the...
Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report
Greatest ROI Opportunity for Consumers in Shortest Period of Time
WASHINGTON, Jan. 27 /PRNewswire/ -- As the new administration examines the potential investment in targeted therapies that utilize personalized medicine to improve patient care, a new report released today by the Deloitte Cente...
Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process
MONTREAL, Oct. 22 /PRNewswire/ -- Global Vision, the leader in
automated proofreading solutions for the pharmaceutical industry announced
today that 15 of the top 20 pharmaceutical companies have selected Global
Vision to help them reduce the risk of textual and artwork errors from
Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
BERKELEY HEIGHTS, N.J., March 27 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) announced that the NASDAQ Listing
Qualifications Panel has granted the Company's request for an extension of
time to achieve
full compliance with the applicable NASDAQ listing
requirements. Pursuant ...
Boston College, MIT researchers achieve dramatic increase in thermoelectric efficiency
CHESTNUT HILL/CAMBRIDGE, Mass., March 20, 2008 - Researchers at Boston College and MIT have used nanotechnology to achieve
a major increase in thermoelectric efficiency, a milestone that paves the way for a new generation of products from semiconductors and air conditioners to car exhaust systems...
Novavax Reports Second Quarter 2009 Financial Results
...ntly sponsored by ROVI and the Spanish authorities, will be formed and funded to support Phase III clinical development and other studies necessary to achieve
market authorization of the VLP-based influenza vaccines in the European Union, which is targeted for 2012.
Raised $21.9 million from the sale ...
ThermoGenesis Announces Expanded Collaboration With Celling Technologies
...oduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve
the revenue levels we expect for fiscal 2010 and 2010. A more complete description of these and other risks that could cause actual events to differ ...
ThermoGenesis Provides Update on Fiscal 2009 Results
... business and our new products--the MXP and Res-Q--we will be positioned to achieve
meaningful growth in revenues during 2010," Engle added. "We expect to end...d result in a materially different revenue outcome and/or in our failure to achieve
the revenue levels we expect for fiscal 2010 and 2010. Revenue and loss are...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...rical change in percent predicted FVC.
While CAPACITY 1 did not achieve
statistical significance on the primary endpoint at Week 72, the results we...linical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve
statistical significance on the primary endpoint in one of its two pivotal ...
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
... product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma or to achieve
market acceptance for such treatments, the possibility that priority review will not be granted by the FDA for the pixantrone NDA and that a decision ...
The Breast Cancer Therapeutics Market in Australia
...ies for growth.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve
best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with...
New clues about a hydrogen fuel catalyst
...gen fuel system that stores hydrogen safely and discharges hydrogen easily, which can then be used in fuel cells or other applications.
One way to achieve
such a fuel system is by "storing" hydrogen as part of a larger molecule. The molecule that contains hydrogen atoms, in this case ammonia borane, serv...
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
...Study, which was performed at the request of the FDA. We believe that with this updated review timeline, if we gain approval in November, we may still achieve
our overall goal of launching Qutenza in the United States in the first half of 2010."
Conference Call Details
The Company will hold i...
NxStage Reports Second Quarter 2009 Financial Results
...nge of $42 to $47 million or ($0.90) to ($1.01) per share, and for an Adjusted EBITDA loss in the range of $13 to $18 million. The Company expects to achieve
consolidated gross margins of between 27 percent to 32 percent in the fourth quarter of 2009.
For the third quarter of 2009, the Company is f...
New angle on gecko research
...ances place a premium on grip over outright speed," says Russell.
In the case of the geckos, the intricate way that the toes are used in order to achieve
the grip necessary to climb is responsible for slowing them.
Russell and Higham are both evolutionary biologists and study animals in their natur...
Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
...lopment, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve
these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results o...
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
...nsplant centers in the United States and France. Although orBec(R) did not achieve
statistical significance in the primary endpoint of its pivotal trial, name...ian time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did achieve
statistical significance in other key secondary endpoints such as the propo...
SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
...ng statements. Such statements include, but are not limited to, statements regarding: Senomyx's rights to the remaining license fee and our ability to achieve
the specified events for receiving such payment; Senomyx's ability to discover and develop novel flavor ingredients for use as sweet enhancers of sucr...
Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
... sales of our product will increase as the farmers have
the opportunity to directly experience the dramatic impact on crop yields and
quality they can achieve
from applying our product."
Each distributor sources successful, independently owned stores within
their assigned territories that have typical...
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
...id dosing through use of Intermezzo ((R)); and the ability of Transcept to achieve
its goal of becoming a fully integrated specialty pharmaceutical company. Transcept may not actually achieve
the plans, intentions or expectations disclosed in our forward-looking stat...
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
...tients will continue to receive SOC. Patients who achieve
undetectable levels of virus at weeks 4 and 12 wil...ility for patients in the ANA598 Phase II study to achieve
undetectable levels of virus at weeks 4 and 12 and to achieve
SVR; (iii) Anadys' expectation that it will receiv...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
...or 48. The primary endpoint of the study is the proportion of patients who achieve
undetectable levels of virus at week 12 ( c omplete E arly V irological ...ciated with the reduction in force and facilities move; (vi) the ability to achieve
EVR, RVR and SVR in the Phase II study; (vii) the expectation to begin pati...
PDI Appoints Gerald P. Belle as Lead Independent Director
...s in an ever-changing environment. As such, I look forward to working with PDI management and my fellow board members who remain committed to helping achieve
the Company's growth goals while maintaining the highest standards of corporate governance," stated Mr. Belle.
From 2004 until his retirement i...
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
... be between $2.59 and $2.67. The company now believes that it is likely to achieve
the upper end of the adjusted diluted earnings per share guidance range. W...based on preliminary estimates and there can be no assurance that Endo will achieve
Includes all completed business development transactio...
Caliper Life Sciences Reports Second Quarter 2009 Results
...pro forma revenue. In addition, the Company reaffirmed its expectation to achieve
positive earnings before interest, taxes, depreciation, amortization and st...s and its ability to attain cash flow breakeven performance, its ability to achieve
positive earnings before interest, taxes, depreciation, amortization and st...
BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
...ommercial prospects of those industries, Verenium's dependence on existing collaboration, manufacturing, and/or license agreements, and its ability to achieve
milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products...
Sanofi-aventis Announces Second Quarter 2009 Results
...urring cost savings(6) in 2013 relative to 2008. These savings will be achieved across all Group functions.
Our aim is therefore to achieve
at least the same level of sales in 2013 vs. 2008 before any significant external growth opportunities. Key growth drivers (Vaccines, Diabetes product...
Breaking barriers with nanoscale lasers
...worked only in a low-temperature operating environment. The next step is to achieve
the same laser light emission at room temperature.
"We discovered we were working on the same problems and trying to achieve
similar goals using similar ideas," he says. "So the partnership developed....
Cynosure Reports Second Quarter 2009 Financial Results
...ompared with first six months of 2008, largely through the cost-reduction efforts we put in place early this year," Davin said. "We remain on track to achieve
our previously stated goal of annualized operating expense savings of between $14 million and $18 million in 2009. We were cash flow neutral in the s...
PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
...ns of human growth hormone, erythropoietin, interferon beta, GLP-1, and other products; that the long-acting products in development may fail, may not achieve
the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications ...
PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
...long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve
the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications ...
Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
...ut Frost & Sullivan - "We Accelerate Growth"
Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve
best in class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with...
Free Webinar on Safer Clinical Hand-Offs Offered by Compirion Healthcare
...c Imaging, Materials Management, Inpatient, Outpatient and Nursing Care improvement projects. Compirion contracts only for measurable outcomes to help achieve
patient satisfaction, staff loyalty and a better bottom line.
For more information on Compirion's sustainable healthcare solutions, call 1-86...
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
...nical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products) , its ability to achieve
clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, inc...
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy
...ndomised into MoxDuo(TM) IV or morphine IV groups over a two-part, 48-hour treatment period. In Part 1, rapid dosing will be used by the physician to achieve
maximal reductions in pain. In Part 2, patients will manage their own pain relief on an "as needed" basis using self-administered PCA (patient control...
Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
...S. diagnostic business, developing strategic investment and action plans to achieve
U.S. market leadership for key Roche business platforms, directing efforts ... strategy for high value technologies were aligned with the market needs to achieve
peak product sales faster.
"This is one of the more exciting tec...
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
...ing market conditions. We continued to invest in new products, in sales and marketing initiatives and in facilities that are expected to enable us to achieve
above-market rate organic sales growth. And we plan to continue to drive process improvements through our supply chain initiative and manage costs pru...